Cell-specific activation of the human skeletal alpha-actin by androgens.
Although it is evident that androgens increase muscle mass and strength, little is known about the critical molecular targets of androgens in skeletal muscle. In rodents, the skeletal alpha-actin gene is a tissue-specific gene expressed only in the levator ani and other skeletal muscles but not in the prostate or preputial gland, the well-known androgen target tissue. We identified tissue-specific androgen-regulated genes in the skeletal muscle in rats after oral administration of androgens and focused on androgen-dependent up-regulation of the skeletal alpha-actin gene. To investigate the mechanism of action, an in vitro system with various cell lines and a series of deletion mutants of the alpha-actin promoter were used. The human skeletal alpha-actin promoter was activated by androgens in the muscle cell line C2C12 but not in the liver, prostate, or breast cancer cell lines in which exogenous human androgen receptor is expressed. The sequence of the promoter is sufficient for cell-specific androgen response, providing a model for the tissue specificity demonstrated in vivo. Using a series of deletion mutants, the androgen response can be maintained using just the proximal promoter region. The importance of androgen regulation of this small portion of the human skeletal alpha-actin promoter was demonstrated by the correlation between muscle and the alpha-actin promoter activity for an array of selective androgen receptor modulators (SARMs), including an orally active SARM LGD2226. Taken together, the results suggest that the regulation of skeletal alpha-actin by androgens/SARMs may represent an important model system for understanding androgen anabolic action in the muscle.
Hong
Mei Hua
MH
Department of Research and Development, Ligand Pharmaceuticals Inc., 10275 Science Center Drive, San Diego, California 92121, USA. mhong@ligand.com
Sun
Hong
H
Jin
Cheng He
CH
Chapman
Mark
M
Hu
Junlian
J
Chang
William
W
Burnett
Kelven
K
Rosen
Jon
J
Negro-Vilar
Andres
A
Miner
Jeffrey N
JN
D000199:Actins / Q000235:genetics / Q000378:metabolism*; D000634:Aminoquinolines / Q000494:pharmacology; D000728:Androgens / Q000502:physiology*; D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D045744:Cell Line, Tumor; D013196:Dihydrotestosterone / Q000494:pharmacology; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D051379:Mice; D023421:Models, Animal; D008969:Molecular Sequence Data; D018482:Muscle, Skeletal / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D015363:Quinolones / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000378:metabolism; D014162:Transfection
C515129:6-N,N-bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one; D000199:Actins; D000634:Aminoquinolines; D000728:Androgens; D015363:Quinolones; D012333:RNA, Messenger; D011944:Receptors, Androgen; D013196:Dihydrotestosterone